Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...

Blood and urine tests might be able to reveal how much of your diet is made up of industrially produced foods, a new study ...

About a fourth of younger men surveyed in the United States feel lonely, which is significantly higher than the national ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

CALIFORNIA, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- The Type 2 Diabetes market is undergoing significant ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime ...

Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s ...